Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection
New England Journal of Medicine2018Vol. 378(4), pp. 354–369
Citations Over TimeTop 1% of 2018 papers
Stefan Zeuzem, Graham R. Foster, Stanley Wang, Armen Asatryan, Edward Gane, Jordan J. Feld, Tarik Asselah, Marc Bourlière, Peter Ruane, Heiner Wedemeyer, Stanislas Pol, Robert Flisiak, Fred Poordad, Wan‐Long Chuang, Catherine Stedman, Steven L. Flamm, Paul Y. Kwo, Gregory J. Dore, Gladys Sepúlveda-Arzola, Stuart K. Roberts, Ruth Soto-Malave, Kelly Kaita, Massimo Puoti, John M. Vierling, Edward Tam, Hugo E. Vargas, Rafi Bruck, Francisco Fuster García, Seung Woon Paik, Franco Felizarta, Jens Kort, Bo Fu, Ran Liu, Teresa I. Ng, Edward Tam, Chih‐Wei Lin, Roger Trinh, Federico Mensa
Abstract
Once-daily treatment with glecaprevir-pibrentasvir for either 8 weeks or 12 weeks achieved high rates of sustained virologic response among patients with HCV genotype 1 or 3 infection who did not have cirrhosis. (Funded by AbbVie; ENDURANCE-1 and ENDURANCE-3 ClinicalTrials.gov numbers, NCT02604017 and NCT02640157 .).
Related Papers
- Susquehanna Chorale Spring Concert "Roots and Wings"(2017)
- → DETERMINING QUALITY REQUIREMENTS AT THE UNIVERSITIES TO IMPROVE THE QUALITY OF EDUCATION(2018)
- → Genentech taps Affimed’s antibodies(2018)
- Enxerto livre de arteria epigastrica inferior: avaliacao hemodinamica e angiografica pre e pos-operatoria(1988)
- → KOMPLIKASI REGIONAL ANESTESI PADA PEDIATRIK(2023)